Diagnostic Challenges in Thrombotic Microangiopathies - European Medical Journal

Diagnostic Challenges in Thrombotic Microangiopathies

Download PDF
Dirk Kuypers1
Dirk Kuypers,1 Josep Campistol,2 Christophe Legendre3

The authors are invited speakers for Alexion and have received honorarium from Alexion, Astellas, Bristol Myers Squibb, Novartis, Pfizer, and Roche.


Writing assistance provided by Dr Juliet Bell apothecom scopemedical.


Medical writing assistance was funded by Alexion Pharma International. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Alexion.

EMJ Nephrol. ;1[1]:28-36. DOI/10.33590/emjnephrol/10313322. https://doi.org/10.33590/emjnephrol/10313322.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The Alexion Satellite Symposium provided an introduction to thrombotic microangiopathies (TMA) by Prof Dirk Kuypers, who described atypical haemolytic uraemic syndrome (aHUS) as a rare but severe disease that causes TMA and can result in organ failure. Prof Josep Campistol presented two patient cases to illustrate the need to make a differential diagnosis between aHUS, thrombotic thrombocytopaenic purpura (TTP), and Shiga toxin-related-HUS (STEC-HUS). Prof Christophe Legendre then described aHUS clinical management, introduced eculizumab as the only approved treatment for aHUS, and provided an overview of the efficacy and safety data from recent clinical trials.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now